Related Experiment Videos
Neuroleptic malignant syndrome in the elderly
J S Leipsic1, H D Abraham, P Halperin
1Department of Psychiatry, University of California at Davis, USA.
Journal of Geriatric Psychiatry and Neurology
|January 1, 1995
Summary
Neuroleptic Malignant Syndrome (NMS) cases were older and had prior neuropsychiatric issues. Lower neuroleptic doses were used, suggesting a complex cause beyond just medication.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Neuroleptic Malignant Syndrome (NMS) is a rare but serious adverse reaction to antipsychotic medications.
- Identifying risk factors and understanding NMS pathogenesis is crucial for patient safety.
Purpose of the Study:
- To investigate the characteristics of neuroleptic malignant syndrome (NMS) cases in a general hospital setting.
- To explore potential contributing factors including patient demographics, medication details, and premorbid conditions.
Main Methods:
- Retrospective case review of four NMS patients identified over five years.
- Analysis of patient age, sex, neuroleptic potency/dose, premorbid history, prodromal symptoms, treatment, and outcomes.
Main Results:
- NMS cases were significantly older (mean age 14 years greater) than the general patient population.
- All NMS patients had pre-existing neuropsychiatric disorders and identifiable prodromal symptoms.
- The average neuroleptic dose administered was lower than previously reported in NMS literature.
Conclusions:
- A systems model is proposed, integrating premorbid factors, concurrent illnesses, and drug effects in NMS development.
- Findings suggest that patient-specific vulnerabilities and illness context play a significant role in NMS, even with lower drug doses.